Page 17 - Pharma Stocks
Pharma supply start-up Saveo Healthcare raises $4.5mn in venture round
Company founded by 4 IIT graduates will use money to expand its presence and for improving technology
 "Pharma supply start-up Saveo Healthcare raises $4.5mn in venture round")
Aurobindo slips 6% in a week after arm receives EIR from USFDA
In the past six months, Aurobindo has underperformed the market by falling 31 per cent, as compared to a marginal 0.07 per cent decline in the S&P BSE Sensex.
 "Aurobindo slips 6% in a week after arm receives EIR from USFDA")
Prescription for recovery in FY23 for underperforming pharma sector
Easing pricing pressures, complex generics uptick in the US, steady India/emerging-market growth potential booster shots
 "Prescription for recovery in FY23 for underperforming pharma sector")
Analysts cautious on Fortis Healthcare post SC verdict; stock tanks 18%
Apart from a forensic audit in the Fortis-IHH deal, the Supreme Court on Thursday also announced a jail term of six months for Malvinder Singh and Shivinder Singh in the Daiichi-Fortis case.
 "Analysts cautious on Fortis Healthcare post SC verdict; stock tanks 18%")
Growth forecast in US market set to drive gains for Cipla stock
Street remains bullish on India prospects, regulatory headwinds for Goa site continue
 "Growth forecast in US market set to drive gains for Cipla stock")
Nifty Pharma index sees biggest jump in four months, shows data
The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year
 "Nifty Pharma index sees biggest jump in four months, shows data")
SEBI asks pharma companies to disclose details that can impact stock prices
The details that need to be disclosed are new drugs, pending patents, source of raw materials, and new partnerships, among others
 "SEBI asks pharma companies to disclose details that can impact stock prices")
Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.
 "Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts")
Dr Reddy's gains over 3% on new drug launch in the US market
The company launched its generic version of fesoterodine fumarate extended-release tablets that can be used for treating overactive bladder in the US market.
 "Dr Reddy's gains over 3% on new drug launch in the US market")
Tarsons Products hits 8-month high on heavy volume; soars 20% in a week
In the past six months, the stock soared 32 per cent, as against 9 per cent decline in the S&P BSE Sensex.
 "Tarsons Products hits 8-month high on heavy volume; soars 20% in a week")
Biocon slips 4% despite arm denying bribery charges
At 10:26 AM, the stock of Biocon was down 3 per cent at Rs 316.10, as compared to 1 per cent decline in the S&P BSE Sensex
 "Biocon slips 4% despite arm denying bribery charges")
Gland Pharma rides high on valuation comfort, strong growth prospects
Target prices post brokerage upgrades point to more upsides
 "Gland Pharma rides high on valuation comfort, strong growth prospects")
Stocks to Watch: LIC, Bata, AUSFB, Bharat Dynamics, REL, SBI Cards, HDFC Bk
Stocks to Watch Today: AU Small Finance Bank will be in focus as the company has set June 10 as the record date for the proposed 1:1 bonus issue.
 "Stocks to Watch: LIC, Bata, AUSFB, Bharat Dynamics, REL, SBI Cards, HDFC Bk")
Divis Labs sheds 14% in two days, hits 52-week low post Q4 results
The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.
 "Divis Labs sheds 14% in two days, hits 52-week low post Q4 results")
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
 "Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%")
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21
 "Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results")
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 quarter.
 "Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations")
Sun Pharma slips over 2% after USFDA issues observations for Halol facility
In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period
 "Sun Pharma slips over 2% after USFDA issues observations for Halol facility")
Stocks to Watch: ICICI Bank, RIL, Tejas Network, Tata Metaliks, Religare
Stocks to Watch Today: Shares of pharma company - Aurobindo, Sun Pharma and Jubilant are likely to be in focus as the trio have recalled different products in the US market as per the latest USFDA
Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%
The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.
 "Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%")
